# A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

> **NCT05540860** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Edgewise Therapeutics, Inc.** · enrollment: 76 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** Sevasemten Dose 1
- **DRUG:** Sevasemten Dose 2
- **DRUG:** Sevasemten Dose 3
- **DRUG:** Sevasemten Dose 4
- **DRUG:** Sevasemten Dose 5
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05540860
- **Lead sponsor:** Edgewise Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-24
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2025-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05540860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05540860, "A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05540860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*